Page 149 - Read Online
P. 149

Zacharakis et al. Hepatoma Res 2018;4:65  I  http://dx.doi.org/10.20517/2394-5079.2018.76                                     Page 11 of 15


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               None.

               Conflicts of interest
               All authors declared that there are no conflicts of interest.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2018.

               REFERENCES
               1.   Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, et al. The burden of primary liver cancer
                   and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.
                   JAMA Oncol 2017;3:1683-91.
               2.   Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, et al. Global burden of cancer in 2008: a systematic analysis of
                   disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840-50.
               3.   Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
               4.   Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, et al. Population attributable fractions of risk factors for
                   hepatocellular carcinoma in the United States. Cancer 2016;122:1757-65.
               5.   Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology
                   2004;127:S35-50.
               6.   Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C
                   virus infection. Gastroenterology 2011;140:1182-8.
               7.   El-Serag HB. Hepatocellular Carcinoma. N Engl J Med 2011;365:1118-27.
               8.   Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol
                   2004;130:417-22.
               9.   Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, et al. Combinations of biomarkers and Milan criteria for predicting
                   hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015;21:559-606.
               10.  Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously
                   treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
               11.  Umeda S, Kanda M, Kodera Y. Emerging evidence of molecular biomarkers in hepatocellular carcinoma. Histol Histopathol 2018;33:343-
                   55.
               12.  Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and
                   their promise for therapeutics. Hepatol Int 2017;11:45-53.
               13.  Di Costanzo A, Del Gaudio N, Migliaccio A, Altucci L. Epigenetic drugs against cancer: an evolving landscape. Arch Toxicol 2014;88:1651-
                   68.
               14.  Dhanak D, Jackson P. Development and classes of epigenetic drugs for cancer. Biochem Biophys Res Commun 2014;455:58-69.
               15.  Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-
                   independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006;43:425-34.
               16.  Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular
                   carcinoma: a multicenter phase i/ii study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II
                   Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012;30:3361-7.
               17.  Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumor Biol 2013;34:2075-91.
               18.  Peterson ML, Ma C, Spear BT. Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene
                   reactivation during liver cancer. Semin Cancer Biol 2011;21:21-7.
               19.  Grizzi F, Colombo P, Taverna G, Chiriva-Internati M, Cobos E, et al. Geometry of human vascular system: is it an obstacle for quantifying
                   antiangiogenic therapies? Appl Immunohistochem Mol Morphol 2007;15:134-9.
               20.  Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr 2014;3:410-4.
               21.  Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: surveillance, diagnosis and prediction of
                   prognosis. World J Hepatol 2015;7:139-49.
   144   145   146   147   148   149   150   151   152   153   154